<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7822">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005106</url>
  </required_header>
  <id_info>
    <org_study_id>STRATA2016</org_study_id>
    <nct_id>NCT03005106</nct_id>
  </id_info>
  <brief_title>StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements</brief_title>
  <official_title>A Phase III Open-label, Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of StrataGraft Skin Tissue in Promoting Autologous Skin Tissue Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements and for Which Excision and Autografts Are Clinically Indicated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stratatech, a Mallinckrodt Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stratatech, a Mallinckrodt Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed registration study is designed as a phase III open-label, controlled,
      randomized, multicenter study evaluating the efficacy and safety of StrataGraft skin tissue
      in promoting autologous skin tissue regeneration of complex skin defects due to thermal
      burns. The proposed study will include patients with 3-49% total body surface area (TBSA)
      complex skin defects due to thermal burns with intact dermal elements for which excision and
      autografting are clinically indicated. The study has been designed to focus on the
      evaluation of efficacy and safety of StrataGraft skin tissue, while also assessing the
      potential for StrataGraft skin tissue to promote healing of complex skin defects due to
      thermal burns as an alternative to donor site harvesting and autografting. Targeted
      enrollment for this study is up to 70 subjects with complex skin defects caused by thermal
      burns that containing intact dermal elements and for which surgical excision and autografts
      are clinically indicated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in the percent area of the StrataGraft treatment site and control autograft treatment site that is autografted by 3 months</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects achieving durable wound closure of the StrataGraft treatment site at 3 months without autograft placement</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Trauma-related Wound</condition>
  <condition>Burns</condition>
  <condition>Skin Wound</condition>
  <arm_group>
    <arm_group_label>StrataGraft Skin Tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>StrataGraft Skin Tissue</intervention_name>
    <description>StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).</description>
    <arm_group_label>StrataGraft Skin Tissue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autograft</intervention_name>
    <arm_group_label>StrataGraft Skin Tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subject-specific criteria:

          1. Men and women aged ≥ 18 years

          2. Written informed consent

          3. Sufficient healthy skin identified and reserved as a donor site in the event that the
             StrataGraft treatment site requires autografting

          4. Clinical expectation that the study donor site will heal without grafting

          5. Complex skin defects of 3-49% TBSA

               -  Total burn may consist of more than one area

             Treatment site-specific criteria:

          6. Thermal burn(s) with intact dermal elements for which excision and autografting are
             clinically indicated

          7. Total of both study treatment areas can be up to 2000 cm2

          8. First excision and grafting of study treatment sites

          9. Thermal burn(s) on the torso, arms, or legs

        Exclusion Criteria

        Subject-specific criteria:

          1. Pregnant women

          2. Prisoners

          3. Subjects receiving systemic immunosuppressive therapy

          4. Subjects with a known history of malignancy

          5. Preadmission insulin-dependent diabetic subjects

          6. Subjects with concurrent conditions that in the opinion of the investigator may
             compromise subject safety or study objectives

          7. Expected survival of less than three months

          8. Participation in the treatment group of an interventional study within 90 days prior
             to enrollment

             Treatment site-specific criteria:

          9. Full-thickness burns

         10. Chronic wounds

         11. The face, head, neck, hands, feet, buttocks, and area over joints

         12. Treatment sites immediately adjacent to unexcised eschar

         13. Clinical or laboratory determination of infection at the anticipated treatment sites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary A Lokuta, PhD</last_name>
    <phone>608-441-2750</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Burn Center at Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kevin N. Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtiy of California - Irvine Health Regional Burn Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hayley Blacker, BSN</last_name>
      <email>hblacker@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Pham</last_name>
      <email>jacquekp@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Joe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracey MacDermott</last_name>
      <email>tracey.macdermott@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa McLawhorn</last_name>
      <email>melissa.m.mclawhorn@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Shupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital - Regional Burn Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Karlnoski, PhD</last_name>
      <email>rkarlnos@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Center Firefighters Burn Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Arnold-Ross, MSN RN NP-C</last_name>
      <phone>901-448-2525</phone>
      <email>aarnoldr@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>William Hickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkland Memorial Hospital Regional Burn Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.S. Army Institute of Surgical Research Adult Burn Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234-6315</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Hatem, RN</last_name>
      <phone>210-916-6152</phone>
      <email>victoria.d.hatem.civ@mail.mil</email>
    </contact>
    <investigator>
      <last_name>LTC Booker T King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia St. Mary's Regional Burn Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Lenhardt</last_name>
      <email>dlenhard@columbia-stmarys.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 22, 2016</lastchanged_date>
  <firstreceived_date>December 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
